Innovating Works

ASPIVIX

Financiado
Vacuum Medical Device for Safe and Gentle Cervix Grasping Gynecological Applicat...
For years, gynecologist practices related to Intra-Uterine Contraceptive Device (IUCD) insertions, curettage and several other common indications, have featured poor care and low attention to female patients.
The use of the Tenacu... For years, gynecologist practices related to Intra-Uterine Contraceptive Device (IUCD) insertions, curettage and several other common indications, have featured poor care and low attention to female patients.
The use of the Tenaculum, grasping and pulling on the cervix, inside the vaginal cavity, proved to be painful and traumatic for 84% of the women, and eventually to trigger lesions and bleeding in 29% of the patients, as well as cross-contamination in 5-10% of the women. These disadvantages refrain the use of IUCD contraceptive which exacerbates the unintended pregnancies, sized yearly in 85 mills and representing billions of euros in social costs worldwide. In response, we have developed Aspivix, a new disruptive gynecological device that reduces the pain and eradicates the bleeding during the exploration procedure. Our patented device will replace the Tenaculum forceps, unchanged for over 100 years, to provide gynecologists an easy-to-use device where gentle and firm cervix uterus grasping and traction is needed. Thus, our device will facilitate the adoption of IUCD, which could avoid up to 8% of unintended pregnancies and reduce derived social costs. Besides, Aspivix is intended for a single use which prevents the risk of contamination and cross-infection. Overall, Aspivix has the potential to shorten the intervention procedure (2 steps instead 7), which will represent for the physician a 28% economic benefit. As result, Aspivix will fulfill the needs of more than 64 M of women worldwide/year, a market that is projected to grow at a CAGR2016-2021 of ~6.5% due to the high demand of IUCD insertions and is valued in more than €350M. In this way, thanks to the sales of 22M units in the European, Asian and North American Markets after 5-years, Aspivix will generate cumulative revenues of nearly €80 M and, considering the total investment of €3.6M, a return of investment (ROI) of €8.3 per euro invested. ver más
31/08/2018
ASPIVIX
71K€
Duración del proyecto: 4 meses Fecha Inicio: 2018-04-30
Fecha Fin: 2018-08-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2018-08-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 71K€
Líder del proyecto
ASPIVIX SA No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5